Ex vivo delivery of GDNF maintains motor function and prevents neuronal loss in a transgenic mouse model of Huntington's disease

Experimental Neurology

Volumn 224, Issue 1, 2010, Pages 155-162

  Ebert, Allison D ^a,b   Barber, Amelia E ^b   Heins, Brittany M ^b   Svendsen, Clive N ^a,b,c  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Gene therapy; Neural progenitor cells; Striatum; Transplantation

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GREEN FLUORESCENT PROTEIN; HUNTINGTIN; NEURON SPECIFIC NUCLEAR PROTEIN; POLYGLUTAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LOSS; CELL SURVIVAL; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE MODEL; EX VIVO STUDY; FEMALE; GENE EXPRESSION; GENE TARGETING; HISTOPATHOLOGY; HUNTINGTON CHOREA; LENTIVIRINAE; MALE; MOTOR PERFORMANCE; MOUSE; NERVE CELL; NEURAL STEM CELL; NEURAL STEM CELL TRANSPLANTATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN SECRETION; ROTAROD TEST; SURVIVAL RATE; TRANSGENIC MOUSE;

ANALYSIS OF VARIANCE; ANIMALS; BODY WEIGHT; CELL COUNT; CELLS, CULTURED; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; GENE THERAPY; GENETIC VECTORS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUNTINGTON DISEASE; IMMUNOHISTOCHEMISTRY; LENTIVIRUS; MICE; MICE, TRANSGENIC; MICROSCOPY, CONFOCAL; MOTOR ACTIVITY; NERVE DEGENERATION; NEURONS; ROTAROD PERFORMANCE TEST; STEM CELL TRANSPLANTATION;

EID: 77953701829     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2010.03.005     Document Type: Article

References (43)

1. Armstrong R.J., Watts C., Svendsen C.N., Dunnett S.B., Rosser A.E. Survival, neuronal differentiation, and fiber outgrowth of propagated human neural precursor grafts in an animal model of Huntington's disease. Cell Transplant. 2000, 9:55-64.
2. Bachoud-Levi A.C., Remy P., Nguyen J.P., Brugieres P., Lefaucheur J.P., Bourdet C., Baudic S., Gaura V., Maison P., Haddad B., Boisse M.F., Grandmougin T., Jeny R., Bartolomeo P., Dalla B.G., Degos J.D., Lisovoski F., Ergis A.M., Pailhous E., Cesaro P., Hantraye P., Peschanski M. Motor and cognitive improvements in patients with Huntington's disease after neural transplantation. Lancet 2000, 356:1975-1979.
3. Bakshi A., Shimizu S., Keck C.A., Cho S., Lebold D.G., Morales D., Arenas E., Snyder E.Y., Watson D.J., McIntosh T.K. Neural progenitor cells engineered to secrete GDNF show enhanced survival, neuronal differentiation and improve cognitive function following traumatic brain injury. Eur. J. Neurosci. 2006, 23:2119-2134.
4. Behrstock S., Ebert A., McHugh J., Vosberg S., Moore J., Schneider B., Capowski E., Hei D., Kordower J., Aebischer P., Svendsen C.N. Human neural progenitors deliver glial cell line-derived neurotrophic factor to parkinsonian rodents and aged primates. Gene Ther. 2006, 13:379-388.
5. Ben-Shaanan T.L., Ben-Hur T., Yanai J. Transplantation of neural progenitors enhances production of endogenous cells in the impaired brain. Mol. Psychiatry 2008, 13:222-231.
6. Benchoua A., Trioulier Y., Diguet E., Malgorn C., Gaillard M.C., Dufour N., Elalouf J.M., Krajewski S., Hantraye P., Deglon N., Brouillet E. Dopamine determines the vulnerability of striatal neurons to the N-terminal fragment of mutant huntingtin through the regulation of mitochondrial complex II. Hum. Mol. Genet. 2008, 17:1446-1456.
7. Bibb J.A., Yan Z., Svenningsson P., Snyder G.L., Pieribone V.A., Horiuchi A., Nairn A.C., Messer A., Greengard P. Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:6809-6814.
8. Bjugstad K.B., Redmond D.E., Teng Y.D., Elsworth J.D., Roth R.H., Blanchard B.C., Snyder E.Y., Sladek J.R. Neural stem cells implanted into MPTP-treated monkeys increase the size of endogenous tyrosine hydroxylase-positive cells found in the striatum: a return to control measures. Cell Transplant. 2005, 14:183-192.
9. Capowski E.E., Schneider B.L., Ebert A.D., Seehus C.R., Szulc J., Zufferey R., Aebischer P., Svendsen C.N. Lentiviral vector-mediated genetic modification of human neural progenitor cells for ex vivo gene therapy. J. Neurosci. Methods 2007, 163:338-349.
10. Cha J.H.J., Kosinski C.M., Kerner J.A., Alsdorf S.A., Mangiarini L., Davies S.W., Penney J.B., Bates G.P., Young A.B. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:6480-6485.
11. Charvin D., Roze E., Perrin V., Deyts C., Betuing S., Pages C., Regulier E., Luthi-Carter R., Brouillet E., Deglon N., Caboche J. Haloperidol protects striatal neurons from dysfunction induced by mutated huntingtin in vivo. Neurobiol. Dis. 2008, 29:22-29.
12. Choi-Lundberg D.L., Lin Q., Chang Y.N., Chiang Y.L., Hay C.M., Mohajeri H., Davidson B.L., Bohn M.C. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 1997, 275:838-841.
13. Cicchetti F., Saporta S., Hauser R.A., Parent M., Saint-Pierre M., Sanberg P.R., Li X.J., Parker J.R., Chu Y., Mufson E.J., Kordower J.H., Freeman T.B. Neural transplants in patients with Huntington's disease undergo disease-like neuronal degeneration. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:12483-12488.
14. Deglon N., Tseng J.L., Bensadoun J.C., Zurn A.D., Arsenijevic Y., Pereira d.A., Zufferey R., Trono D., Aebischer P. Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease. Hum. Gene Ther. 2000, 11:179-190.
15. Ebert A.D., Beres A.J., Barber A.E., Svendsen C.N. Human neural progenitor cells over-expressing IGF-1 protect dopamine neurons and restore function in a rat model of Parkinson's disease. Exp. Neurol. 2008, 209:213-223.
16. Eriksson C., Wictorin K. Neuronal and glial differentiation within expanded glial cultures derived from the lateral and medial ganglionic eminences. Exp. Neurol. 2003, 184:1058-1063.
17. Eriksson C., Bjorklund A., Wictorin K. Neuronal differentiation following transplantation of expanded mouse neurosphere cultures derived from different embryonic forebrain regions. Exp. Neurol. 2003, 184:615-635.
18. Freeman T.B., Cicchetti F., Hauser R.A., Deacon T.W., Li X.J., Hersch S.M., Nauert G.M., Sanberg P.R., Kordower J.H., Saporta S., Isacson O. Transplanted fetal striatum in Huntington's disease: phenotypic development and lack of pathology. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:13877-13882.
19. Georgievska B., Kirik D., Bjorklund A. Overexpression of glial cell line-derived neurotrophic factor using a lentiviral vector induces time-and dose-dependent downregulation of tyrosine hydroxylase in the intact nigrostriatal dopamine system. J. Neurosci. 2004, 24:6437-6445.
20. Gill S.S., Patel N.K., Hotton G.R., O'Sullivan K., McCarter R., Bunnage M., Brooks D.J., Svendsen C.N., Heywood P. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 2003, 9:589-595.
21. Hickey M.A., Reynolds G.P., Morton A.J. The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease. J. Neurochem. 2002, 81:46-59.
22. Imitola J., Raddassi K., Park K.I., Mueller F.J., Nieto M., Teng Y.D., Frenkel D., Li J., Sidman R.L., Walsh C.A., Snyder E.Y., Khoury S.J. Directed migration of neural stem cells to sites of CNS injury by the stromal cell-derived factor 1alpha/CXC chemokine receptor 4 pathway. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:18117-18122.
23. Jakel R.J., Maragos W.F. Neuronal cell death in Huntington's disease: a potential role for dopamine. TINS 2000, 23:239-245.
24. Keene C.D., Sonnen J.A., Swanson P.D., Kopyov O., Leverenz J.B., Bird T.D., Montine T.J. Neural transplantation in Huntington disease: long-term grafts in two patients. Neurology 2007, 68:2093-2098.
25. Kendall A.L., Rayment F.D., Torres E.M., Baker H.F., Ridley R.M., Dunnett S.B. Functional integration of striatal allografts in a primate model of Huntington's disease. Nat. Med. 1998, 4:727-729.
26. Kobayashi S., Ogren S.O., Hoffer B.J., Olson L. Dopamine D-1 and D-2 receptor-mediated acute and long-lasting behavioral effects of glial cell line-derived neurotrophic factor administered into the striatum. Exp. Neurol. 1998, 154:302-314.
27. Lang A.E., Gill S., Patel N.K., Lozano A., Nutt J.G., Penn R., Brooks D.J., Hotton G., Moro E., Heywood P., Brodsky M.A., Burchiel K., Kelly P., Dalvi A., Scott B., Stacy M., Turner D., Wooten V.G., Elias W.J., Laws E.R., Dhawan V., Stoessl A.J., Matcham J., Coffey R.J., Traub M. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol. 2006, 59:459-466.
28. McBride J.L., During M.J., Wuu J., Chen E.Y., Leurgans S.E., Kordower J.H. Structural and functional neuroprotection in a rat model of Huntington's disease by viral gene transfer of GDNF. Exp. Neurol. 2003, 181:213-223.
29. McBride J.L., Behrstock S.P., Chen E.Y., Jakel R.J., Siegel I., Svendsen C.N., Kordower J.H. Human neural stem cell transplants improve motor function in a rat model of Huntington's disease. J. Comp. Neurol. 2004, 475:211-219.
30. McBride J.L., Ramaswamy S., Gasmi M., Bartus R.T., Herzog C.D., Brandon E.P., Zhou L., Pitzer M.R., Berry-Kravis E.M., Kordower J.H. Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:9345-9350.
31. Nutt J.G., Burchiel K.J., Comella C.L., Jankovic J., Lang A.E., Laws E.R., Lozano A.M., Penn R.D., Simpson R.K., Stacy M., Wooten G.F. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 2003, 60:69-73.
32. Ostenfeld T., Caldwell M.A., Prowse K.R., Linskens M.H., Jauniaux E., Svendsen C.N. Human neural precursor cells express low levels of telomerase in vitro and show diminishing cell proliferation with extensive axonal outgrowth following transplantation. Exp. Neurol. 2000, 164:215-226.
33. Ourednik J., Ourednik V., Lynch W.P., Schachner M., Snyder E.Y. Neural stem cells display an inherent mechanism for rescuing dysfunctional neurons. Nat. Biotechnol. 2002, 20:1103-1110.
34. Palfi S., Conde F., Riche D., Brouillet E., Dautry C., Mittoux V., Chibois A., Peschanski M., Hantraye P. Fetal striatal allografts reverse cognitive deficits in a primate model of Huntington disease. Nat. Med. 1998, 4:963-966.
35. Petersen A., Puschban Z., Lotharius J., NicNiocaill B., Wiekop P., O'Connor W.T., Brundin P. Evidence for dysfunction of the nigrostriatal pathway in the R6/1 line of transgenic Huntington's disease mice. Neurobiol. Dis. 2002, 11:134-146.
36. Ramaswamy S., McBride J.L., Herzog C.D., Brandon E., Gasmi M., Bartus R.T., Kordower J.H. Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington's disease. Neurobiol. Dis. 2007, 26:375-384.
37. Ramaswamy S., McBride J.L., Han I., Berry-Kravis E.M., Zhou L., Herzog C.D., Gasmi M., Bartus R.T., Kordower J.H. Intrastriatal CERE-120 (AAV-Neurturin) protects striatal and cortical neurons and delays motor deficits in a transgenic mouse model of Huntington's disease. Neurobiol. Dis. 2009, 34:40-50.
38. Rosenblad C., Georgievska B., Kirik D. Long-term striatal overexpression of GDNF selectively downregulates tyrosine hydroxylase in the intact nigrostriatal dopamine system. Eur. J. Neurosci. 2003, 17:260-270.
39. Schilling G., Becher M.W., Sharp A.H., Jinnah H.A., Duan K., Kotzuk J.A., Slunt H.H., Ratovitski T., Cooper J.K., Jenkins N.A., Copeland N.G., Price D.L., Ross C.A., Borchelt D.R. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum. Mol. Genet. 1999, 8:397-407.
40. Sherer T.B., Fiske B.K., Svendsen C.N., Lang A.E., Langston J.W. Crossroads in GDNF therapy for Parkinson's disease. Mov. Disord. 2006, 21:136-141.
41. Slevin J.T., Gerhardt G.A., Smith C.D., Gash D.M., Kryscio R., Young B. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J. Neurosurg. 2005, 102:216-222.
42. Wang L.J., Lu Y.Y., Muramatsu S., Ikeguchi K., Fujimoto K., Okada T., Mizukami H., Matsushita T., Hanazono Y., Kume A., Nagatsu T., Ozawa K., Nakano I. Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of amyotrophic lateral sclerosis. J. Neurosci. 2002, 22:6920-6928.
43. Winkler C., Fricker R.A., Gates M.A., Olsson M., Hammang J.P., Carpenter M.K., Bjorklund A. Incorporation and glial differentiation of mouse EGF-responsive neural progenitor cells after transplantation into the embryonic rat brain. Mol. Cell. Neurosci. 1998, 11:99-116.